Pharmaceuticals Malaysia

Malaysia Newborn Genome Sequencing Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Malaysia Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $0.7 Mn Placeholder estimate
Estimate 2025 $0.9 Mn 0.2% of the global market
Projected 2034 $4.5 Mn 423.8% Adds $3.7 Mn over 9 forecast years
CAGR 2025–2034 20.2% Faster than 86% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Malaysia is 0.2% of the global market.
  • In APAC, the largest is China at $33.1 Mn.
  • Fastest growing: India at 23% a year.
  • Malaysia ranks 7th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Newborn Genome Sequencing Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $0.7 Mn — —
2025 (base) $0.9 Mn +$0.1 Mn —
2026 (forecast) $1.0 Mn +$0.2 Mn +20.2%
2027 (forecast) $1.3 Mn +$0.2 Mn +44.5%
2028 (forecast) $1.5 Mn +$0.3 Mn +73.7%
2029 (forecast) $1.8 Mn +$0.3 Mn +108.7%
2030 (forecast) $2.2 Mn +$0.4 Mn +150.9%
2031 (forecast) $2.6 Mn +$0.4 Mn +201.6%
2032 (forecast) $3.1 Mn +$0.5 Mn +262.5%
2033 (forecast) $3.8 Mn +$0.6 Mn +335.7%
2034 (forecast) $4.5 Mn +$0.8 Mn +423.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $432.0 Mn
  2. US $190.9 Mn
  3. North America $184.9 Mn
  4. APAC $96.3 Mn
  5. Europe $89.1 Mn
  6. Canada $36.6 Mn
  7. China $33.1 Mn
  8. Japan $23.5 Mn
  9. Latin America $22.5 Mn
  10. Middle East $15.8 Mn
  11. Germany $13.7 Mn
  12. UK $12.2 Mn
  13. Brazil $12.3 Mn
  14. Italy $11.7 Mn
  15. France $10.8 Mn
  16. Ecuador $9.6 Mn
  17. India $8.6 Mn
  18. Spain $8.0 Mn
  19. Mexico $6.6 Mn
  20. Saudi Arabia $6.5 Mn
  21. Africa $5.9 Mn
  22. Australia $5.4 Mn
  23. New Zealand $5.1 Mn
  24. Russia $4.3 Mn
  25. South Africa $2.8 Mn
  26. UAE $2.1 Mn
  27. Egypt $1.3 Mn
  28. Philippines $1.0 Mn
  29. Malaysia (this report) $0.9 Mn
  30. Hong Kong $0.7 Mn
  31. Thailand $0.6 Mn
  32. Singapore $0.4 Mn
  33. Kenya $0.3 Mn

Report snapshot

Malaysia Newborn Genome Sequencing Market Analysis at a glance
Market size, 2025$0.9 Mn placeholder estimate
Forecast, 2034$4.5 Mn placeholder estimate
Growth (CAGR), 2025–203420.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProgram, condition and end user (see all)
Key playersIllumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia Newborn Genome Sequencing Market Analysis Executive Summary

Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.

Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).

Bar chart: Malaysia Newborn Genome Sequencing market size, 2024–2034, placeholder estimates. $0.7 Mn in 2024, $0.9 Mn in 2025 and $4.5 Mn in 2034, 20.2% CAGR.
Malaysia Newborn Genome Sequencing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia Newborn Genome Sequencing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.

Competitive Landscape for Newborn Genome Sequencing Market in Malaysia

The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Newborn Genome Sequencing Market in Malaysia

Newborn Genome Sequencing in Malaysia: rules and payment

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.

Latest research 53 papers since 2021 (worldwide)

  1. Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening. Disease models & mechanisms, 2026
  2. Corrigendum to "Complexity of genomic diagnosis: Lessons learnt from the UK Biobank and Generation study newborn genome sequencing analyses" [Bone 212 (2026) 118009]. Bone, 2026
  3. Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS. Genetics in medicine : official journal of the American College of Medical Genetics, 2026
  4. Complexity of genomic diagnosis: Lessons learnt from the UK Biobank and Generation study newborn genome sequencing analyses. Bone, 2026
  5. Genomic newborn screening as a paradigm shift in rare disease management, with emphasis on endocrine conditions. Annales d'endocrinologie, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Newborn Genome Sequencing in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Newborn Genome Sequencing market in Malaysia?
Placeholder estimate: about $0.9 Mn in 2025, rising to about $4.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Newborn Genome Sequencing market in Malaysia growing?
Placeholder estimate: about 20.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Newborn Genome Sequencing market report cover?
The report splits the market by program (Research Programs, National Screening Pilots, Private Testing), condition (Metabolic, Immune, Neurological, Cardiac) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Newborn Genome Sequencing market?
Key players include Illumina, Inc., GeneDx, Natera, Genomics England and Fulgent Genetics.
What is driving the Newborn Genome Sequencing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Who regulates Newborn Genome Sequencing in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How much research is published on Newborn Genome Sequencing?
PubMed lists 53 papers on Newborn Genome Sequencing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Newborn Genome Sequencing in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Cord Blood Banking: Is It Worth It?Doctors' groups such as ACOG support public cord blood donation, but say routine private banking is not… From Melghat, With Hope: How a Tribal Region is Redefining Newborn CareLow-cost digital tools empower tribal nurses, cutting newborn deaths through innovation
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on genomics and neonatal

See the topic